B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Value Share, Analysis and Segments 2016-2024

Multiple myeloma is an incurable disease of plasma cells, which needs some intervention by clinical researchers. However, there have been recent success in developing such therapy that can be effective in hematologic malignancies such as chimeric antigen receptor CAR-T cell therapy, which is expected to be promising in cancer treatment. However, researchers have found little success in finding a specific target antigen under CAR T-cell therapies for treating multiple myeloma. Though, there have been recent studies that suggest a targeted effect of B-cell maturation antigen (BCMA) that has been effective in cells with multiple myelomas. BCMA is a protein, which is selectively expressed by B-lineage cells that directly work on cells with multiple myelomas. Researchers are still working to determine the compatibility in target for CAR-expressing T cells for BCMA. Furthermore, B-cell maturation antigen (BCMA) is a vital biomarker of the B-cells that is a promising and newly emerged therapeutic target to treat multiple myeloma and other hematological malignancies.

Request a sample copy of this report: https://www.coherentmarketinsights.com/insight/request-sample/190

Multiple myeloma affected cells are considered to be having B-cell maturation antigen. This has led to various studies related to BCMA targeted therapies in the recent past. Multiple myeloma is the second-most common type of hematological malignancy, which affects a large population. According to the American Cancer Society, in 2017, around 30,280 new cases are estimated to be diagnosed, leading to around 2,600 deaths. Middle-aged men exposed to any type of radiation or chemicals a past history of monoclonal gammopathy of undetermined significance (MGUS) are most at risk of contracting multiple myeloma. Increasing awareness among the research community and renewed efforts across the globe to effectively treat cancer and related diseases is expected to provide major traction for growth of the BCMA targeted therapies market in the foreseeable future.

BCMA Targeted Therapies Market Taxonomy:

By Product Type

CAR-T cells
Bispecific Antibodies
Antibody Drug Conjugates
By End User

Hospitals
Cancer Research Institutes


Increase in prevalence of multiple myeloma globally is expected to support growth of BCMA targeted therapies market:

Multiple myeloma can be fatal and is linked with frequent events of re-occurrence of the disorder along various other serious complications associated with it. The globally widespread prevalence of the disorder and B-cell malignancies needs specific and targeted diagnosis and treatments. Hence, there is an immediate requirement for targeted and effective therapies to provide appropriate medical care. This in turn is expected to favor growth of BCMA market in the near future. Multiple myeloma is characterized by the clonal proliferation of plasma cells in bone marrow, which leads to bone destruction, renal abnormalities, anemia and hypercalcemia. The rise in prevalence of multiple myelomas in the population around the globe is projected to underpin the growth expansion of targeted therapies in BCMA market in the near future. According to National Institutes of Health and National Cancer Institute, in 2013, in the U.S., there were around 96,000 people living with myeloma.

Browse report summery with TOC: https://www.coherentmarketinsights.com/ongoing-insight/toc/190

Specificity and targeted effect on cancer cells is projected to favor growth of the BCMA targeted therapies market

B cell maturation antigen, is the member of the tumor necrosis factor receptor group and a type III membrane protein containing one extracellular cysteine rich domain, which has been designated as TNFRSF17. The specificity of the therapy to treat the patients affected from multiple myelomas is projected to be one of the vital factors favoring growth in adoption of B-Cell Maturation Antigen targeted therapies in the near future. Furthermore, collaboration between the existing players in the B-Cell Maturation Antigen market is expected to be one of the crucial factor in its growth, this will further expected to enhance the company’s product portfolio over the forecast period.

Key players operating in the BCMA targeted therapies market include Celgene Corporation, bluebird bio, Poseida Therapeutics, Inc., Juno Therapeutics, Eureka Therapeutics,

Click here to know more about this report: https://www.coherentmarketinsights.com/ongoing-insight/bcma-targeted-therapies-market-190

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

CONTACT US:

Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel : +1-206-701-6702
Email: sales@coherentmarketinsights.com
Website: https://www.coherentmarketinsights.com

This release was published on openPR.